On August 2 2023, PULMONX CORPORATION ($NASDAQ:LUNG) reported their earnings results for FY2023 Q2, ending June 30 2023. Total revenue for the quarter was USD 17.2 million, which represented a 23.2% increase compared to the same period in the previous year. Net income for the period was reported to be USD -16.2 million, compared to -14.6 million in the same quarter of FY2022.
The stock opened at $13.6 and closed at $13.2, a decrease of 4.2% from the prior closing price of 13.8. Overall, PULMONX CORPORATION reported a successful second quarter for FY2023, demonstrating its ability to respond effectively to challenging market conditions and maintain financial stability despite the decreased revenue and profits. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Pulmonx Corporation. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Pulmonx Corporation. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Pulmonx Corporation. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Pulmonx Corporation are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we are dedicated to helping our customers analyze the fundamentals of PULMONX CORPORATION. Our analysis reveals that PULMONX CORPORATION has an intermediate health score of 4/10 in terms of cashflows and debt, indicating that the company might be able to safely ride out any crisis without the risk of bankruptcy. We have classified PULMONX CORPORATION as a ‘cheetah’, a type of company that has achieved high revenue or earnings growth but is considered less stable due to lower profitability.This makes it an attractive company for investors looking for higher growth potential, though they should also be aware of its associated risk. When it comes to PULMONX CORPORATION’s strengths and weaknesses, we find that it is strong in asset, growth, and weak in dividend, profitability. This suggests that investors should be aware of the risks associated with this company before investing. More…
Risk Rating Analysis
Star Chart Analysis
Its competitors include Sonendo Inc, Verisante Technology Inc, and Glaukos Corp.
Sonendo Inc. is a publicly traded company with a market capitalization of $76.48 million as of March 2022. The company’s return on equity (ROE) is -64.45%. Sonendo Inc. is a dental technology company that develops, manufactures, and markets products and services for the dental industry worldwide. The company’s products and services include the GentleWave System, a minimally invasive root canal treatment system; and the EndoSequence Root Repair Material, a biocompatible material used to repair root canal defects.
– Verisante Technology Inc ($OTCPK:VRSEF)
Verisante Technology Inc is a medical technology company that develops and commercializes cancer detection systems. The company’s products include the Aura, a hand-held device that uses light to identify skin cancer; and the Core, a desktop unit that uses light and lasers to identify various types of cancer. Verisante Technology Inc has a market cap of 545.1k as of 2022, a Return on Equity of 12.19%. The company’s products are designed to provide early detection of cancer, which can lead to better patient outcomes.
Glaukos Corporation is a medical technology company focused on the development and commercialization of therapeutic solutions for the eye. The company’s products are designed to improve patient outcomes by reducing intraocular pressure, or IOP, which is the primary driver of glaucoma progression. Glaukos has a market cap of $2.58 billion as of 2022 and a return on equity of -4.53%. The company’s products are used by ophthalmologists to treat patients with glaucoma, a condition in which IOP is elevated.
Investors were disappointed with the earnings report of PULMONX CORPORATION for FY2023 Q2, which ended June 30th 2023. Total revenue for the quarter was USD 17.2 million, a year-over-year increase of 23.2%, however the company reported a net loss of USD -16.2 million, compared to -14.6 million in the same quarter of the previous year. This resulted in immediate downward pressure on the company’s stock price. Going forward, investors will be closely watching for any indication of a turnaround in the fortunes of PULMONX CORPORATION in order to determine whether it is a good investment opportunity.